BTG2 Inhibitors
BTG2 inhibitors constitute a diverse class of compounds that exert their effects through the modulation of specific signaling pathways and cellular processes. A key member of this class is A769662, an AMP-activated protein kinase (AMPK) activator. By enhancing AMPK phosphorylation, A769662 influences cellular metabolism, indirectly impacting BTG2 expression through energy-sensing mechanisms. Additionally, BAY 11-7082, an inhibitor of IkappaB kinase (IKK), disrupts the NF-κB pathway. This interference leads to downstream effects on gene expression, indirectly influencing BTG2 modulation as NF-κB regulates genes interacting with BTG2. Other notable members include GSK 3 Inhibitor IX, a glycogen synthase kinase 3 (GSK-3) inhibitor that affects the Wnt signaling pathway. Inhibition of GSK-3 indirectly modulates BTG2 activity by influencing β-catenin degradation. LY294002, a PI3-kinase inhibitor, disrupts the PI3-kinase/Akt pathway, known to regulate BTG2 expression, thus offering another avenue for indirect modulation. Furthermore, Nocodazole, a microtubule-depolymerizing agent, interferes with BTG2 expression by disrupting the cell cycle through its impact on microtubule dynamics.
Rapamycin, an mTOR inhibitor, affects protein synthesis and cell growth, indirectly influencing BTG2 expression through mTOR signaling modulation. Similarly, SB203580, a p38 MAPK inhibitor, disrupts stress response signaling, indirectly impacting BTG2 levels in response to cellular stress. SP600125, a JNK inhibitor, modulates the MAPK pathway, indirectly influencing BTG2 expression. Triciribine, an AKT inhibitor, targets Akt in the PI3-kinase/Akt pathway, providing another avenue for indirect BTG2 modulation. U0126, a MEK inhibitor affecting the MAPK pathway, disrupts MAPK signaling, influencing BTG2 expression indirectly. Wortmannin, a PI3-kinase inhibitor, modulates the PI3-kinase/Akt pathway, providing another mechanism for indirect BTG2 modulation. The collective action of these diverse compounds highlights the intricate network of pathways and cellular processes through which BTG2 inhibitors exert their effects, underscoring their potential as valuable tools in elucidating BTG2-related cellular functions.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
AMP-activated protein kinase (AMPK) activator. A769662 increases AMPK phosphorylation, leading to downstream effects on cellular metabolism. By influencing AMPK-mediated pathways, it indirectly modulates BTG2 expression and function, possibly through energy-sensing mechanisms. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
IKK inhibitor targeting the NF-κB pathway. BAY 11-7082 disrupts the NF-κB signaling cascade, impacting downstream gene expression. BTG2 has known interactions with NF-κB-regulated genes, and inhibition of this pathway can indirectly influence BTG2 modulation. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Hedgehog signaling pathway inhibitor. Cyclopamine disrupts the Hedgehog pathway, which cross-talks with BTG2 through various signaling events. Modulation of Hedgehog signaling can indirectly affect BTG2 expression and function. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
Glycogen synthase kinase 3 (GSK-3) inhibitor. GSK 3 Inhibitor IX affects the Wnt signaling pathway by inhibiting GSK-3, an enzyme involved in β-catenin degradation. As BTG2 interacts with components of the Wnt pathway, inhibition of GSK-3 can indirectly influence BTG2 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3-kinase inhibitor. LY294002 disrupts the PI3-kinase/Akt pathway, which is implicated in various cellular processes. BTG2 is known to be regulated by PI3-kinase signaling, and inhibition of this pathway can indirectly modulate BTG2 expression. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Microtubule-depolymerizing agent. Nocodazole disrupts microtubule dynamics, affecting cellular processes like mitosis. BTG2 expression is cell cycle-dependent, and interference with microtubule dynamics can indirectly influence BTG2 levels by disrupting the cell cycle progression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor. Rapamycin inhibits the mTOR signaling pathway, impacting protein synthesis and cell growth. BTG2 is influenced by mTOR activity, and modulation of this pathway can indirectly affect BTG2 expression and function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor. SB203580 inhibits p38 MAPK, a kinase involved in stress response signaling. BTG2 expression is regulated by stress-related pathways, and inhibition of p38 MAPK can indirectly modulate BTG2 levels in response to cellular stress. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor. SP600125 inhibits c-Jun N-terminal kinase (JNK), a component of the MAPK signaling pathway. BTG2 is known to be modulated by MAPK pathways, and inhibition of JNK can indirectly influence BTG2 expression by disrupting MAPK signaling. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
AKT inhibitor. Triciribine inhibits Akt, a key player in the PI3-kinase/Akt pathway. BTG2 is regulated by Akt signaling, and inhibition of Akt can indirectly modulate BTG2 expression and function. | ||||||